reported the TKI sensitivity in a small cohort of lung adenocarcinomas bearing uncommon exon 19 mutations, Which described two advanced LADC patients with EGFR p.L747_T751delinsP mutation and p.T751_I759delinsS respectively who have only 2-month PFS on gefitinib therapy (22). This evidence concerns the gene EGFR and lung adenocarcinoma.